Accelerating progress in global cancer treatment

David Humphreys
David Humphreys
Global Practice Lead, Health Policy, Economist Enterprise

18 Sept 2023

Accelerating progress in global cancer treatment

Cancer remains a critical health and societal issue with rising incidence rates, delays in care delivery during the pandemic and the number of lives it impacts worldwide. The renewed focus on promising innovations and personalised approaches opens an exciting path forward, though there are risks to falling back into past siloed behaviours and entrenched positions. Our most recent work in oncology research distils these challenges to offer actionable roadmaps for future success—whether that be in the latest therapies, the needs of key demographics or the circumstances affecting different regions.

Cell and Gene Therapies (CGTs): Health system progress in moving from cutting edge to common practice

Sponsored by Gilead

This study reviews the current availability of CGTs and estimates future numbers of therapies that are likely to come onto the market up to 2031. Understand the challenges the technology presents to various healthcare actors and explore a scorecard which examines how well prepared nine countries (Australia, Canada, France, Germany, Italy, Japan, Spain, UK and US) are for rolling out CGTs.

Impact and opportunity: the case for investing in women’s cancers in Asia Pacific

Sponsored by APAC Women's Cancer Coalition and Roche

The burden of women’s cancer (specifically breast and cervical cancer) is examined in six countries in the APAC region: India, Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Using a benchmarking scorecard, thise research examines and compares the quality of policies and programmes to tackle cancer based on recommendations set by the World Health Organisation (WHO).

Rising to the metastatic breast cancer (MBC) challenge: current and future policy responses

Sponsored by Sanofi

This report highlights the diversity of challenges that people with MBC face around the world. It further identifies priorities for policymakers, advocacy organisations, health system administrators and other key stakeholders to improve the quality of life for individuals with MBC.